Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bardoxolone Methyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 known ✓ | Q16236 | 3/20 | 1.00 |
| ▸ | KEAP1 known ✓ | Q14145 | 2/20 | 0.83 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 1.00 |
| ▸ | USP7 | Q93009 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | RORC | P51449 | 1/20 | 0.86 |
| ▸ | NOS2 | P35228 | 9/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CCR6 | P51684 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bardoxolone Methyl SCHEMBL18910897 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL15184347 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL19635256 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL91615 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL12521530 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL18572802 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL23896957 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL21577829 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL22213797 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 | |
| Bardoxolone Methyl SCHEMBL25906069 | 1.00 | MBOAT4 (1.00) | MBOAT4NFE2L2USP7USP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | claimed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | claimed |
| US-10760129-B2 | Th17 differentiation markers for acne and uses thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-09-01 | — | — | US | claimed |
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-11-05 | — | — | US | claimed |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2019-03-14 | — | — | US | claimed |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-01-08 | — | — | US | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| US-20170056373-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | SYRACUSE UNIVERSITY (US) | 2017-03-02 | — | — | US | claimed |
| US-20160326590-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-11-10 | — | — | US | claimed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | claimed |
| US-8981144-B2 | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-03-17 | — | — | US | claimed |
| EP-2793876-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | Ares Trading S.A. (CH) | 2014-10-29 | — | — | EP | claimed |
| US-20140235475-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | claimed |
| US-20140221648-A1 | TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2014-08-07 | — | — | US | claimed |
| US-20140221231-A1 | TH-17 DIFFERENTIATION MARKERS FOR ROSACEA AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-07 | — | — | US | claimed |
| EP-2723890-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | Galderma Research & Development (FR) | 2014-04-30 | — | — | EP | claimed |
| US-20130303797-A1 | METHOD FOR SYNTHESIZING 2-CYANO-3,12-DIOXOOLEAN-1, 9(11)-DIEN-28-OIC ACID METHYL ESTER AND DERIVATIVES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-11-14 | — | — | US | claimed |
| WO-2013092269-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | claimed |
| WO-2013000870-A1 | NEW TH17 DIFFERENTIATION MARKERS FOR ACNE AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303797-A1 | METHOD FOR SYNTHESIZING 2-CYANO-3,12-DIOXOOLEAN-1, 9(11)-DIEN-28-OIC ACID METHYL ESTER AND DERIVATIVES THEREOF | HAAO, CYP8B1, OXER1 | NFE2L2 3039/4885KEAP1 1464/4885MBOAT4 303/4885 |
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 3721/4885 |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 3721/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 3721/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 2888/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 3656/4885 |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | NFE2L2 3/4885KEAP1 2/4885MBOAT4 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.